GleamWall
中文EN

HRMY Harmony Biosciences Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1802665 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY19.8%
TTM net income YoY-3.8%
TTM EPS YoY-4.7%
Revenue 3-yr CAGR22.2%
Net income 3-yr CAGR5.8%

Margins

Gross margin74.0%
Operating margin22.2%
Net margin18.1%
FCF margin—
EBITDA margin—

Returns

ROE18.7%
ROA13.3%
ROIC (approx.)36.1%
Asset turnover0.74x

Leverage & solvency

Liabilities / assets27.5%
Debt / equity0.14x
Current ratio3.44x
Interest coverage16.99x

Cash quality & payout

Operating cash flow / net income1.81x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$868.45M$714.73M
Cost of revenue$198.34M$156.81M
Gross profit$670.11M$557.92M
R&D expense$189.59M$145.82M
SG&A expense$152.54M$110.35M
Operating income$208.47M$190.83M
Interest expense$14.65M$17.50M
Pretax income$215.06M$191.80M
Income tax$56.38M$46.31M
Net income$158.69M$145.49M
EBITDA—$191.09M
EPS (basic)2.762.56
EPS (diluted)2.712.51
Weighted avg. shares (diluted)58.54M57.87M
Balance sheet
Cash & equivalents$752.50M$453.27M
Short-term investments$22.84M$14.19M
Receivables$96.79M$83.03M
Inventory$5.36M$7.20M
Current assets$907.01M$579.25M
PP&E, net—$1.26M
Intangibles$89.42M$113.26M
Total assets$1.27B$999.20M
Current liabilities$252.13M$175.08M
Short-term debt$20.00M$16.25M
Long-term debt$143.66M$163.02M
Total debt$163.66M$179.27M
Total liabilities$401.41M$340.05M
Shareholders' equity$870.22M$659.15M
Net debt-$588.84M-$274.00M
Shares outstanding57.73M57.14M
Cash flow statement
Operating cash flow$348.20M$219.82M
Capital expenditure$310,000$1.15M
Free cash flow$347.89M$218.67M
Investing cash flow-$39.65M-$67.48M
Financing cash flow-$9.05M-$11.00M
Depreciation & amortization—$267,000
Stock-based compensation$44.90M$42.60M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.